Cohen C, Davis KL, Meyers JL. Association of partial adherence (PA) to antiretroviral therapy with hospitalizations and healthcare costs in an HIV population. Poster presented at the 11th International Congress on Drug Therapy in HIV Infection; November 2012.
Christiansen CF, Pedersen L, Sorensen HT, Rothman KJ. Methods to assess seasonal effects in epidemiological studies of infectious diseases-exemplified by application to the occurrence of meningococcal disease. Clin Microbiol Infect. 2012 Oct 1;18(10):963-9.
Mauskopf J, Brodan A, Martin S, Smets E. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA. Pharmacoeconomics. 2012 Oct;28 Suppl 1:83-105. doi: 10.2165/11587470-000000000-00000
Mannino S, Villa M, Apolone G, Weiss NS, Groth N, Aquino I, Boldori L, Caramaschi F, Gattinoni A, Malchiodi G, Rothman KJ. Effectiveness of adjuvanted influenza vaccination in elderly subjects in Northern Italy. Am J Epidemiol. 2012 Sep 1;176(6):527-33.
King RM, Vidrine DJ, Danysh HE, Fletcher FE, McCurdy S, Arduino RC, Gritz ER. Factors associated with nonadherence to antiretroviral therapy in HIV-positive smokers. AIDS Patient Care STDS. 2012 Aug;26(8):479-85. doi: 10.1089/apc.2012.0070
Williams V, Rousculp MD, Price M, Coles T, Therrien MA, Griffin J, Hollis K, Toback S. Elementary school-located influenza vaccine programs: key stakeholder experiences from initiation to continuation. J Sch Nurs. 2012 Aug 1;28(4):256-67.
Armbruster B, Lucas AM. Effectiveness of a no-sex or safe-sex month in reducing HIV transmission. Bull World Health Organ. 2012 Jul;90(7):477-556. doi: 10.2471/BLT.11.088641
DiFranza JR, Masaquel A, Barrett AM, Colosia AD, Mahadevia PJ. Systematic literature review assessing tobacco smoke exposure as a risk factor for serious respiratory syncytial virus disease among infants and young children. BMC Pediatr. 2012 Jun 1;12:81.
Mauskopf J, Talbird S, Standaert B. Categorization of methods used in cost-effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models. Expert Rev Pharmacoecon Outcomes Res. 2012 Jun 1;12(3):357-71.
Mladsi D, Curtis S, Bell MJ, Ito T, Wilson M, Aboud M. Resource utilisation and cost of managing adverse events (AEs) associated with highly active antiretroviral therapy (HAART) in patients with HIV-1. Poster presented at the 18th Annual Conference of the British HIV Association; April 1, 2012. Birmingham, UK. [abstract] HIV Med. 2012 Apr 18; 13(SI):17-8.
Colosia AD, Masaquel A, Hall CB, Barrett AM, Mahadevia PJ, Yogev R. Residential crowding and severe respiratory syncytial virus disease among infants and young children: a systematic literature review. BMC Infect Dis. 2012 Apr 1;12:95.
Cohen C, Davis KL, Meyers JL. Effect of daily antiretroviral pill burden on hospitalizations in United States medicaid enrollees with HIV: an analysis of hospital characteristics and costs. Poster presented at the 24th Annual Meeting of the Academy of Managed Care Pharmacy; April 2012.
Gritz ER, Vidrine DJ, Marks RM, Danysh HE, Arduino RC. A cell phone-delivered intervention for HIV-positive smokers: project reach out. Poster presented at the Society for Research on Nicotine and Tobacco Annual Meeting; March 15, 2012. Houston, TX.
Poulos C, Riewpaiboon A, Stewart JF, Clemens J, Guh S, Agtini M, Sur D, Islam Z, Lucas M, Whittington D. Costs of illness due to endemic cholera. Epidemiol Infect. 2012 Mar 1;140(03):500-9.
Auzinger G, Playford G, Graham CN, Narula H, Charbonneau C, Weinstein D. Cost-effectiveness analysis of anidulafungin in the treatment of candidaemia. Poster presented at the International Symposium of Intensive Care and Emergency Medicine; March 2012.
Sax PE, Meyers JL, Mugavero M, Davis KL. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured hiv patients in the United States. PLoS One. 2012 Feb 24;7(2):e31591.
Reau N, Hamzeh FM, Lentz E, Zhou X, Jensen D. Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. J Viral Hepat. 2012 Feb;19(2):94-102.
Kauf TL, Davis KL, Earnshaw SR, Davis EA. Spillover adherence effects of fixed-dose combination HIV therapy. Patient Prefer Adherence. 2012 Feb 1;6:155-64.
Mauskopf J, Brogan AJ, Talbird SE, Martin S. Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection. AIDS. 2012 Jan 1;26(3):355-64.
Toback SL, Beigi R, Tennis P, Sifakis F, Calingaert B, Ambrose CS. Maternal outcomes among pregnant women receiving live attenuated influenza vaccine. Influenza Other Respi Viruses. 2012 Jan 1;6(1):44-51.
Sansgiry SS, Joish VN, Boklage S, Goyal RK, Chopra P, Sethi S. Economic burden of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Med Econ. 2012;15(2):219-24. doi: 10.3111/13696998.2011.638954
Earnshaw SR, Candrilli SD, Fernandes AW, Higashi MK. A cost-effectiveness analysis of antibiotic therapy in macrolide-resistant community-acquired pneumonia. Managed Care Interface. 2005 Oct 1;18(10):36-44.
Poulos C, Malik R, Guh S, Utomo N, Nyamete A. Household demand for typhoid fever vaccines in North Jakarta, Indonesia. Poster presented at the Investing in Health, the 5th World Congress of the International Health Economists Association; July 2005. Amsterdam, The Netherlands.
Tafesse E, Claxton A, Granger AL, Sanders J, Apelian D, Atillasoy E, Iloeje U. Estimates of health care costs for lamivudine-refractory chronic hepatitis b (CHB) patients. Poster presented at the 2005 ISPOR 10th Annual International Meeting; May 18, 2005. [abstract] Value Health. 2005 May; 8(3):310.
Richter A, Pladevall M, Manjunath R, Lafata JE, Xi H, Simpkins J, Brar I, Markowitz N, Iloeje U, Irish W. Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV-infected patients: a retrospective cohort study. HIV Med. 2005 Mar 1;6(2):79-90.